Oregon was among the last places in the country where fentanyl took hold. For years, the state’s drug supply ran on heroin — a market that kept illicitly manufactured fentanyl largely out of the Pacific Northwest while it was devastating communities east of the Mississippi. Then, between 2019 and 2023, everything changed.
By 2023, Oregon had recorded 1,833 overdose deaths — the highest in its history — and the largest single-year increase in fentanyl fatalities of any state in the nation. A drug that arrived late arrived with devastating speed.
This guide explains why. It covers how fentanyl entered Oregon’s drug supply, what the data shows about who was most affected, and why this drug creates a different kind of danger than the opioids that came before it.
Why Did Fentanyl Arrive in Oregon Later Than the Rest of the Country?
The United States has moved through the opioid crisis in waves. The first was driven by prescription painkillers. The second by heroin. Fentanyl — the third wave — didn’t hit all parts of the country at the same time.
A Drug Supply Built Around Heroin
The Pacific Northwest had long been a heroin-dominant market. That infrastructure — the trafficking networks, the user population’s expectations, the existing supply chains — created a degree of insulation from fentanyl that eastern states didn’t have.
By 2018, roughly 90 percent of overdose deaths involving fentanyl were concentrated in 28 states east of the Mississippi River, according to research from Brown University Medical School and RTI International. The West Coast’s heroin-based supply simply hadn’t been replaced yet.
Fentanyl did not appear meaningfully in Oregon’s drug supply until 2019. That year, a federal drug task force covering Oregon and Idaho seized 43 doses of illicitly manufactured fentanyl. Three years later, in 2022, that same task force seized more than 32 million doses.
How the COVID-19 Pandemic Changed Everything
The transition from heroin to fentanyl in Oregon wasn’t gradual. It was sudden.
Fentanyl is produced primarily by drug trafficking organizations operating in Mexico, using chemical precursors sourced from China. It enters the United States and moves north through the I-5 corridor. It is cheaper to produce than heroin, far more potent by weight, and dramatically easier to transport in the quantities needed to supply large markets.
When COVID-19 disrupted global supply chains, those economics accelerated the replacement. The Pacific Northwest was the last region in the country to get fentanyl — and the supply chain disruptions of the pandemic led to a swift transition from a heroin-dominant market to a fentanyl-dominant one, according to OPB’s reporting on the Oregon drug crisis. Oregon’s drug supply became more toxic and more lethal in a very short window of time.
Understanding how fentanyl affects the body — and why it produces dependency so rapidly — helps explain why that transition proved so deadly.
What Do Oregon’s Overdose Numbers Actually Show?
The data tells a clear story: a crisis that built quickly, peaked sharply, and has since begun to decline — though it remains far from resolved.
The Surge: 2020 to 2023
In 2020, Oregon recorded 223 overdose deaths involving illicitly manufactured fentanyl. By 2022, that number had risen to 843 — nearly quadrupling in two years. Fentanyl was involved in 65.5 percent of all overdose deaths in the state that year.
The situation continued to worsen. In 2023, Oregon recorded 1,833 total overdose deaths — the highest in state history. Oregon had the largest single-year increase in fentanyl overdose deaths of any state in the nation that year — a 41 percent rise, according to CDC data reported by KOIN 6 News.
The supply data reflects the scale of what was moving through the state. In 2023 alone, Oregon law enforcement seized more than 3 million counterfeit pills containing fentanyl and 176.8 kilograms of fentanyl powder — nearly all of it moving through I-5 corridor counties designated as high-intensity drug trafficking areas.
This crisis is part of a longer story affecting the entire region. For more context on where it fits in Oregon’s broader drug landscape, see our overview of Oregon’s opioid crisis.
The First Signs of Decline: 2024–2025
2024 marked the first year-over-year decline in Oregon overdose deaths since 2016. The Oregon Health Authority reported 1,544 deaths that year — down from 1,833 in 2023. Preliminary 2025 data puts that figure at approximately 1,100 — a second consecutive year of decline.
That progress is meaningful. It is not a resolution.
More than 90 percent of Oregon’s reported overdose deaths in 2024 involved fentanyl, methamphetamine, or a combination of both. Fentanyl remains the dominant driver of overdose mortality in Oregon, and the gap between the number of people who need treatment and the number who access it remains significant.
Which Communities in Oregon Have Been Hit Hardest?
Fentanyl has not affected Oregon’s communities equally. The overdose data consistently shows that geography, housing status, race, and economic circumstance all shape who bears the worst of it.
Urban Centers and the Unhoused Population
Portland’s Multnomah County has seen some of the highest concentrations of fentanyl-related deaths in the state. In 2023, the county recorded 456 overdose deaths — 251 of them linked to fentanyl among the county’s unhoused population, according to Multnomah County Health Department data.
People experiencing homelessness face compounding risks: limited access to naloxone, no one present to respond during an overdose, and significant barriers to entering treatment. By 2024, those numbers had begun to improve. The county recorded 372 deaths among unhoused residents — an 18 percent decrease — with 183 linked to fentanyl. Expanded naloxone distribution and peer outreach programs have been credited as contributing factors.
Rural Communities
Fentanyl’s reach extends well beyond Oregon’s urban centers. Eastern Oregon counties that saw relatively few overdose deaths before 2020 have since been significantly affected.
In 2023, Umatilla County recorded 13 overdose deaths; Malheur County recorded five deaths and 24 emergency department visits for opioid overdose, according to Oregon Capital Chronicle reporting. Rural communities face a distinct set of challenges: long distances from treatment facilities, cultural barriers around seeking help, and fewer harm reduction resources per capita than urban areas.
Racial and Demographic Disparities
The crisis has not landed equally across Oregon’s population. The Oregon Health Authority reports that Native American and Alaska Native communities, and non-Hispanic Black communities, are disproportionately impacted by substance use disorder and overdose.
Between 2019 and 2023, opioid fatalities among Black Oregonians increased by more than 70 percent, with fentanyl as the leading cause, according to a 2024 Oregon Health Authority report. These disparities reflect long-standing inequities in healthcare access — and they underscore the importance of treatment programs equipped to address co-occurring mental health conditions alongside substance use, not sequentially.
Why Is Fentanyl More Dangerous Than the Opioids That Came Before It?
Fentanyl’s dominance in Oregon’s drug supply is not just a matter of prevalence. It is a matter of pharmacology.
Illicitly manufactured fentanyl is 50 to 100 times more potent than heroin, cheaper to produce, and far easier to ship in quantities sufficient to supply large markets. A lethal dose is measured in micrograms — an amount that cannot be seen without laboratory equipment. This is what makes accidental overdose so common: there is no reliable way to assess dose or purity in the street supply. People with years of opioid tolerance have died from a single exposure to fentanyl-laced product.
Contamination makes this worse. Because fentanyl is economically advantageous to add to other drugs, it has permeated Oregon’s supply well beyond the opioid market. It is now routinely found in counterfeit prescription pills (marketed as M30 oxycodone tablets, colloquially known as “blues”), in methamphetamine, and in other substances where users have no expectation of encountering an opioid. The Oregon Health Authority has noted that smoking is now the primary route of use among overdose deaths in the state — a shift that moves fentanyl exposure away from syringe service programs where harm reduction resources have historically been concentrated.
Polysubstance use adds a third layer of complexity. In 2024, 62.2 percent of Oregon overdose deaths involved multiple substances — with fentanyl and methamphetamine as the most common combination. These combinations affect the body in opposing ways, making overdose recognition harder and emergency response more complex. In October 2024, the Oregon Health Authority issued an alert about xylazine — a veterinary sedative — appearing in Oregon’s fentanyl supply. Unlike fentanyl, xylazine does not respond to naloxone, adding another layer of risk to an already dangerous supply environment.
Getting Help for Fentanyl Addiction in Oregon
Oregon’s treatment access gap is significant. An OHA-commissioned analysis found a statewide 49 percent gap in addiction services capacity — meaning the state’s current system serves roughly half of those who need it. Every county in Oregon was found to be at moderate to high risk of substance-related hospitalization rates above the national median, with rural areas facing the most severe shortfalls.
Effective treatment exists. It typically begins with medical detox — a phase where clinical staff manage withdrawal under 24-hour supervision, stabilizing the body before longer-term care begins. From there, most people benefit from a structured program that incorporates medication-assisted treatment, behavioral therapy, and support for any co-occurring mental health conditions.
At Discover Recovery, we offer a full continuum of care — medical detox, residential treatment, PHP, IOP, and sober living — from locations in Camas and Long Beach, WA, and Portland, OR. Oregon residents don’t have to travel far, and they don’t have to transfer to a new provider as their needs change. We are CARF-accredited, and our programs are overseen by Kevin Fischer, MD (Internal Medicine and Addiction Medicine).
If you or someone you love is ready to take the next step, our team is available around the clock. Call 866.719.2173, or verify your insurance online to understand your coverage before you call.
Frequently Asked Questions
Is Oregon’s fentanyl crisis getting better or worse?
The trend has improved for two consecutive years. Oregon recorded approximately 1,100 overdose deaths in 2025 — down from 1,544 in 2024 and 1,833 in 2023, according to preliminary Oregon Health Authority data. That decline is real and reflects genuine investment in harm reduction, expanded treatment access, and naloxone distribution. But fentanyl remains present in more than 90 percent of Oregon’s overdose deaths, and emergency department visits for overdose remain elevated. The situation is improving; it is not resolved.
How does Oregon compare to other states for fentanyl overdose deaths?
Oregon had the largest single-year increase in fentanyl overdose deaths of any state nationally in 2023 — a 41 percent rise, according to CDC data. This reflects the timing of fentanyl’s arrival: the Pacific Northwest was the last region in the country to be penetrated by illicitly manufactured fentanyl, and the transition compressed years of cumulative impact into a short window. States that were hit earlier — primarily in the Northeast and Midwest — have since seen significant declines, while Alaska, Nevada, Washington, and Oregon moved into the national top 10 for overdose death rates during the same period.
What is driving fentanyl into Oregon?
The primary supply comes from drug trafficking organizations — principally the Sinaloa Cartel and the Jalisco New Generation Cartel — that produce fentanyl in Mexico using chemical precursors sourced from China. Product moves north into the United States and through the I-5 corridor, which serves as the primary distribution route through Oregon. Oregon-Idaho High Intensity Drug Trafficking Area data shows seizures of illicitly manufactured fentanyl in Oregon rose from 43 doses in 2019 to more than 32 million doses in 2022 — a stark measure of how rapidly the supply penetrated the state.
Why does naloxone sometimes not work on a fentanyl overdose?
Fentanyl’s potency means a standard single dose of naloxone may not be sufficient to reverse an overdose — multiple doses are often required. The Oregon Health Authority recommends having multiple naloxone doses on hand for any potential fentanyl-involved overdose. A second complication comes from xylazine: this veterinary sedative, increasingly found mixed into Oregon’s fentanyl supply, does not respond to naloxone at all. Xylazine-involved overdoses require emergency medical care beyond what naloxone alone can provide, making it critical to call 911 even when naloxone has been administered.
What does fentanyl addiction treatment involve for Oregon residents?
Treatment for fentanyl use disorder typically follows a continuum: medical detox first — to manage withdrawal safely under clinical supervision — followed by residential or intensive outpatient treatment that incorporates medication-assisted treatment and behavioral therapy. Many people also benefit from treatment for co-occurring mental health conditions, which are common among people with fentanyl use disorder and are a known driver of relapse when left untreated. Discover Recovery offers this full continuum from locations accessible to Oregon residents. Call 866.719.2173 to speak with our team, or verify your insurance online before you call.
Reviewed By: Dr. Kevin Fischer, M.D.
Kevin Fischer, MD is an experienced leader in the fields of Internal Medicine and Addiction Medicine. He works with patients suffering from Substance Use Disorder to evaluate their comprehensive health needs and prescribe Medication-Assisted Treatment (MAT). In addition, he mentors aspiring health professionals and leads collaborative care through team-based medical models. He also directs treatment strategies and streamlines clinical protocols for effective substance use recovery.